Symeres

What Symeres does

Symeres is a Netherlands-headquartered contract research, development and manufacturing organization (CRDMO) delivering integrated small molecule drug discovery, development and manufacturing services from target assessment through IND-ready packages. Operating under legal entity Symeres B.V. and headquartered in Groningen with 9 connected sites across Europe and North America, the company employs 600+ scientists in a single integrated unit and reports group revenues exceeding €100 million. The company is privately held by Keensight Capital and traces its current form to a Keensight-backed acquisition spree beginning in 2022 (Organix Inc., Exemplify BioPharma, Oncolines) and continuing with DGr Pharma in September 2025.

The service portfolio spans medicinal, synthetic, computational and specialty chemistry; in vitro and in vivo ADME; in vitro toxicology; bioassays and bioinformatics; lipid and polymer drug delivery; process development; preclinical and GMP manufacturing; clinical formulation; solid state chemistry; and ADME-Tox. Specialized technical assets include laboratory- and pilot-scale spray drying at the Cranbury, NJ facility for bioavailability enhancement, a 102-cancer cell line panel for oncology profiling, and a molecular glue profiling platform for difficult-to-drug targets. The company holds ISO 27001 and SBTi certifications, supporting both enterprise pharma procurement criteria and ESG mandates.

Symeres generates revenue through professional services engagements, ranging from standalone studies to fully integrated discovery-to-IND programs under a single program lead. The company sells directly to enterprise through field sales and program-lead-based account management, serving both fast-moving biotechs and global pharmaceutical companies, with named clients spanning top-10 global pharma, dedicated FTE engagements with large European pharma, and earlier-stage biotechs such as Pinotbio, Seamless Therapeutics, Genecode and Supreme Pharma. Pricing is quote-based and not publicly disclosed, consistent with industry norms for custom CRDMO contracts.

Name

Symeres

Legal name

Symeres B.V.

Website

https://symeres.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Symeres is a Netherlands-based CRDMO providing integrated small molecule drug discovery, development, and GMP manufacturing services from target assessment through IND. The company operates 9 connected sites across Europe and North America with 600+ scientists serving biotech and global pharmaceutical clients.

Ownership category

akta.pro rank

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. Contract Research Services (CRO): Symeres generates revenue through contract research organization services including medicinal chemistry, synthetic chemistry, computational chemistry, ADME studies, biology/bioassays, and drug delivery services for biotech and pharma clients.
2. Contract Development and Manufacturing (CDMO): Revenue from drug development services including CMC, GMP manufacturing, clinical formulation development, and analytical services for preclinical through commercial-stage pharmaceutical programs.
3. Integrated Drug Discovery and Development Programs: Fully integrated programs from discovery through IND under one program lead, providing end-to-end services that generate revenue through long-term contracted engagements.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

No source content was provided in the input; the core offering cannot be described without supporting evidence.

Product overview

Symeres is a Contract Research, Development and Manufacturing Organization (CRDMO) providing integrated drug discovery and development services from target assessment through IND-ready packages. The company operates a unified platform combining medicinal chemistry, synthetic chemistry, computational chemistry, specialty chemistry, in vitro ADME, in vivo PK screening, in vitro toxicology, bioassays, bioinformatics, and drug delivery (polymers and lipids) under the drug discovery umbrella. Development services span process development, GMP manufacturing from preclinical through clinical stages, solid state chemistry, formulation and analytical development, and ADME-Tox studies. The company has expanded its spray drying capabilities in Cranbury, NJ for bioavailability enhancement, and collaborates with partners such as Ambagon Therapeutics for molecular glue research in cancer, supported by their 102-cancer cell line panel.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Over €100 million in group revenues following third acquisition
• +2 more outcomes

Named customers6 records

Segments3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• AxxamcoreStrategic or Co-development Partner · 8 July 2026Symeres and biology-driven discovery services provider Axxam jointly appointed Russell Thomas as Chief Scientific Officer to lead their collaborative partnership. The appointment aims to strengthen scientific leadership across both organizations by combining their complementary R&D service capabilities. The integrated offering will support pharmaceutical and biotechnology partners across discovery and development programs, from target assessment through IND-ready packages.
• Ambagon TherapeuticscoreStrategic or Co-development Partner · 1 April 2026Symeres partnered with Ambagon Therapeutics to research molecular glue compounds for colorectal cancer treatment. Under the collaboration, Symeres conducts in vitro assays, mechanistic studies, and compound profiling across its 102-cancer cell line panel, leveraging its translational research capabilities alongside Ambagon's molecular glue technology to generate preclinical data supporting investigational new drug applications.
• Yoneda LabsminorStrategic or Co-development Partner · 26 April 2022Symeres collaborated with Yoneda Labs to optimize chemical reactions, combining Yoneda's reaction optimization capabilities with Symeres' broader drug discovery platform.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Charles River Laboratories: Large global CRO/CDMO with end-to-end drug discovery, development, and manufacturing capabilities across small and large molecules. Directly comparable as a CRDMO serving biotech and pharma clients, though substantially larger and more diversified than Symeres.
• WuXi AppTec: Global CRDMO offering integrated discovery, development, and manufacturing services. Comparable service breadth across small molecule chemistry, biology, and CMC; a much larger player with significantly broader geographic reach.
• Catalent (Novo Holdings): Global CDMO (now under Novo Holdings) offering formulation, clinical and commercial manufacturing. Comparable in CDMO services for small molecules; broader in biologics and commercial-scale drug product.
• Lonza: Leading global CDMO with small molecule and biologics capabilities spanning preclinical through commercial manufacturing. Comparable in CMC/GMP manufacturing, though Lonza's scale, modality coverage, and commercial-stage capacity far exceed Symeres'.
• Labcorp Drug Development (Fortrea): Global CRO/CDMO spun out from Labcorp, offering drug discovery, preclinical, and clinical development services. Comparable in CRO/CDMO scope, though substantially larger and more clinically oriented than Symeres.

Direct peers

• Asymchem: China-based CRDMO specializing in small molecule API development and GMP manufacturing. Directly comparable as a small molecule-focused CDMO serving biotech and pharma, with similar preclinical-through-clinical positioning.
• Jubilant Biosys: India-based CRDMO offering integrated drug discovery and development services for small molecules. Comparable mid-sized integrated discovery CRO with chemistry and biology capabilities targeting similar biotech clients.
• Sai Life Sciences: India-headquartered CRDMO providing drug discovery, development, and manufacturing services for small molecules. Closely comparable mid-sized CRDMO with integrated discovery-to-IND model and similar biotech/pharma customer base.
• Pharmaron: China- and UK-headquartered CRDMO providing integrated drug discovery, preclinical, and CMC services across small molecules. Closely comparable mid-to-large CRDMO with similar integrated model and biotech/pharma customer base.

Emerging players

• Axxam: Biology-driven discovery services provider partnered with Symeres (jointly appointed CSO Russell Thomas in 2026). Adjacent rather than directly competitive, but operates in the same discovery services ecosystem with overlapping biotech customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/symeresbv

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Symeres